WA-SPIE
11.1.2022 18:39:07 CET | Business Wire | Press release
The Awards Committee of SPIE, the international society for optics and photonics , today announced the recipients of its prestigious annual awards . Honoring transformative advancements in multiple areas — including medicine, astronomy, lithography, optical metrology, optical design, and community leadership — the Society's awards recognize technical accomplishments as well as committed service to SPIE and support of its organizational mission.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005942/en/
SPIE Gold Medal: Michael Berns
In recognition of his work in bioengineering research and his distinguished career that brought together engineers, physicists, biologists, and physicians to collaborate on ground-breaking discoveries and innovations.
SPIE President's Award: Tuan Vo-Dinh
In recognition of his outstanding and extensive role in SPIE conference leadership, in disparate technical areas, and for his mentorship of early investigators as well as peers.
SPIE Directors' Award: Julie Bentley
In recognition of her outstanding service to the Society in extraordinary ways, including authorship, course instruction, conference program leadership, committee membership, and service on the Board of Directors.
SPIE Mozi Award: Thomas W. Ebbesen
In recognition of his phenomenal contributions to the field of nano-optics, especially the extraordinary optical transmission through sub-wavelength hole arrays.
SPIE Britton Chance Award in Biomedical Optics: Bruce Tromberg
In recognition of his high-impact translational research and overall leadership in the development of biophotonic technologies for diagnostics and therapeutics.
SPIE Biophotonics Technology Innovator Award: Bert Müller
In recognition of his distinguished contributions to 2D and 3D imaging for the challenges of the 21st century, including cardiovascular and neurodegenerative diseases, bioinspired dental repair, and incontinence treatment.
SPIE Rudolf and Hilda Kingslake Award in Optical Design: Masato Shibuya
In recognition of his significant contributions to the development of optical design through the invention of phase-shift masks for photolithography, and for laying the foundations of imaging theory based on plane-wave expansions.
SPIE Harrison H. Barrett Award in Medical Imaging: Maryellen Giger
In recognition of her pioneering work in the fields of digital image formation, computer-aided diagnosis, radiomics, and radiogenomics.
SPIE Harold E. Edgerton Award in High-Speed Optics: Mona Jarrahi
In recognition of her pioneering contributions to plasmonic time-domain spectroscopy and imaging systems as well as their scientific and industrial applications.
SPIE Dennis Gabor Award in Diffractive Optics: Gabriel Popescu
In recognition of his groundbreaking contributions to holography and quantitative phase imaging for biomedical applications.
SPIE George W. Goddard Award in Space and Airborne Optics: Michelle Stephens
In recognition of her technical innovation, mentoring, and exceptional leadership in pursuit of space-based, fundamental measurements of the Earth and Sun, while reducing technological barriers and promoting standards for the advancement of space and airborne optics.
SPIE G. G. Stokes Award in Optical Polarization: Alex Vitkin
In recognition of his extensive contributions to tissue polarimetry, including advanced methodology developments for sensitive and robust Stokes and Mueller measurements; polarimetric computational and analytical platforms; and biomedical applications including cardiology, regenerative medicine, glucometry, and breast-cancer margin assessment.
SPIE Chandra S. Vikram Award in Optical Metrology: Jürgen Czarske
In recognition of his important contributions to computational laser metrology with paradigm changes in fluid dynamics, inspection, aerospace, communication, and biomedicine.
SPIE Frits Zernike Award for Microlithography: Harry J. Levinson
In recognition of his outstanding achievements contributing to our fundamental understanding of advanced lithography process control, especially in the concepts of Image-Log-Slope, Mask defect printability, and thin-film optics optimization.
SPIE Diversity Outreach Award: Qaisar Abbas Naqvi
In recognition of his inspirational attitude and dedication to students, helping transform the lives of women and men from traditionally under-recognized segments of society by supporting their pursuit of higher education and research in optics and related fields.
SPIE Maria Goeppert-Mayer Award in Photonics: Shin-Tson Wu
In recognition of his seminal contributions to display and photonic device technologies that led to widespread applications.
SPIE Maiman Laser Award: Bill Krupke
In recognition of his scientific, technical and community leadership, innovation, and numerous seminal results in laser science and technology.
SPIE Early Career Achievement Award — Academic Focus: Bhavin Shastri
In recognition of his pioneering efforts in the field of neuromorphic photonics and his contributions to interdisciplinary research across nanophotonics, unconventional computing, and silicon photonics that pushed the frontiers of machine learning.
SPIE Early Career Achievement Award — Industry/Government Focus: Lionel Clermont
In recognition of his significant achievements in the field of stray light control, particularly his work on the development of the ultrafast time-of-flight imaging characterization method.
SPIE Maria J. Yzuel Educator Award: Rajpal Sirohi
In recognition of his many years of service in the field of optics through leadership, capacity building, and outreach.
SPIE Aden and Marjorie Meinel Technology Achievement Award: Ge Wang
In recognition of his pioneering contributions in X-ray and optical molecular tomography, including their coupling for biomedical applications.
The complete listing of all SPIE awards and recipients is available here .
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $22 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110005942/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom